Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07466524 · ClinicalTrials.gov registry record
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
A clinical trial of COVID-19 and Acute Respiratory Distress Syndrome, sponsored by ViroGates A/S.
- Completed
- Registry status
- 367
- Enrollment target
- 1
- Study location
NCT07466524: Completed study of COVID-19 and Acute Respiratory Distress Syndrome, sponsored by ViroGates A/S.
NCT07466524 is a study of COVID-19 and Acute Respiratory Distress Syndrome that has completed, run by ViroGates A/S. The registered enrollment target is 367 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07466524, a study of COVID-19 and Acute Respiratory Distress Syndrome, has completed, sponsored by ViroGates A/S.
- COMPLETED
- Registry status
- 367 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.
Primary Outcome
Development of severe respiratory failure requiring endotracheal intubation and initiation of invasive mechanical ventilation within 30 days of hospital admission. SRF is ascertained from EHR procedure codes and clinical documentation. Performance metrics (sensitivity, specificity, PPV, NPV, AUC) at the suPAR ≥6 ng/mL threshold will be calculated.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST suPARnostic® TurbiLatex Assay on Roche cobas c501
Study Locations (1)
Michigan
- Michigan state university, Department of Biostatistics - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 367 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2022-10-19 |
What the finished NCT07466524 record still lists
NCT07466524 is an observational study that tracks outcomes without assigning an intervention. The registered 367 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which suPARnostic® TurbiLatex Assay on Roche cobas c501 is the first listed.
NCT07466524 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07466524 about?
NCT07466524 is a clinical study titled "suPAR Michigan M2C2 Heterogeneity Validation Cohort Study". This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.
What is the current status of trial NCT07466524?
This trial is currently completed. The enrollment target is 367 participants. The study started on 2020-02-01. Estimated completion is 2022-10-19.
What conditions does trial NCT07466524 study?
This clinical trial studies the following conditions: COVID-19, Acute Respiratory Distress Syndrome, Severe Respiratory Distress Syndrome.
What interventions are being tested in trial NCT07466524?
The interventions under investigation include: suPARnostic® TurbiLatex Assay on Roche cobas c501 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07466524?
This trial is sponsored by ViroGates A/S, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07466524 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07466524's enrollment target sits among peer trials
367 129th of 298 higher than 169 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04675476 · 368 participants · NA
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
- NCT05215353 · 368 participants · Phase 4
A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors
- NCT06182397 · 368 participants · NA
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease
- NCT06629610 · 368 participants · NA
Diet and Active Lifestyle - Yuuyaraq (The Yup'ik Way of Life)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI